Lilly’s Experimental Obesity-Drug Combo Reaches 23.3% Weight Loss—With a Tolerability Caveat

Eli Lilly’s experimental combination of tirzepatide and eloralintide produced up to 23.3% weight loss in a Phase 2 trial involving people with obesity and type 2 diabetes. The 48-week study tested eloraTZP against tirzepatide alone; the combination outperformed Lilly’s existing medicine, according to results reported from the study. That is a striking signal—but “up to” marks the best result, not what every participant should expect.

Plain English

The treatment pairs...